You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

  1. The DETERMINATION trial evaluated patients with newly diagnosed multiple myeloma receiving lenalidomide/bortezomib/dexamethasone with or without autologous stem cell, with median follow-up of 76 months. What was the progression-free survival (PFS) outcome of the study?
    Significantly improved PFS with transplant
    Significantly improved PFS without transplant
    Comparable PFS between the 2 arms